













httpHigh frequency of brachiocephalic trunk stent
fractures does not impair clinical outcome
Edit Dósa, MD, PhD,a Balázs Nemes, MD, PhD,a Viktor Bérczi, MD, PhD, DSc,b
Pál Kaposi Novák, MD, PhD,b Tamás Mirko Paukovits, MD, PhD,a Hunor Sarkadi, MD,a and
Kálmán Hüttl, MD, PhD,a Budapest, Hungary
Objective: Stenting is the preferred, minimally invasive treatment for innominate artery (IA) stenosis or occlusion. Stent
fractures in the IA have not been assessed in larger cohorts. In this retrospective study, we examined the frequency and
risk factors of IA stent fractures.
Methods: The ﬁnal analysis included 32 patients (15 women; mean age, 59.4 6 12.0 years) with 32 balloon-expandable
stents (2000 to 2009). In 2010, the patients were asked to come back for a ﬂuoroscopic examination of the implanted
stents. Stent fractures and their relationship to atherosclerotic risk factors, lesion characteristics, postprocedural symp-
toms, and in-stent restenosis were analyzed. Fisher exact test and univariate Cox regression analysis were used in the
statistical evaluation.
Results: Lesions were >20 mm in 14 patients (44%) or heavily calciﬁed in 13 (41%). The mean follow-up time was 33.4 6
21.0 months. Postprocedural symptoms were noted in nine patients (28%). Signiﬁcant restenosis was detected in 22% of
the implanted stents, and 11 stent fractures (34%) were found. The prevalence of heavily calciﬁed lesions, postprocedural
symptoms, and in-stent restenosis did not differ signiﬁcantly between groups with and without fracture. Long lesions
were associated with an increased incidence of stent fracture (hazard ratio, 5.09; 95% conﬁdence interval, 1.33-19.48;
P [ .017). No correlation was observed between stent fractures and old age ($70 years), female gender, smoking,
hypertension, hyperlipidemia, or diabetes mellitus.
Conclusions: IA stent fractures are common but seem to have no effect on symptoms and in-stent restenosis rates. (J Vasc
Surg 2014;59:781-5.)Innominate artery (IA) stenosis or occlusion can be
asymptomatic or symptomatic. The cerebrovascular symp-
toms include signs of posterior circulation ischemia due
to ﬂow reversal in the right vertebral artery (subclavian steal
syndrome) and, less commonly, transient ischemic attack
(TIA) or stroke as a result of distal embolization. The right
upper extremity symptoms are related to hypoperfusion or
distal embolization.
Endovascular or surgical recanalization procedures are
required in symptomatic patients.1 Percutaneous translu-
minal angioplasty (PTA) combined with stenting was ﬁrst
reported in the 1980s, and since then, has become the
primary treatment of IA stenosis. The efﬁcacy of IA stent-
ing has been validated in follow-up studies, which showed
low complication and high primary patency rates.2-5
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://dx.doi.org/10.1016/j.jvs.2013.09.038Recent studies have extensively investigated stent frac-
tures in the lower limb, coronary, carotid, and vertebral
arteries.6-9 However, with the exception of individual
case reports10,11 and a small survey of nine patients,12 no
comprehensive data have been published on stent fracture
prevalence in the IA. We hypothesized that IA stent frac-
tures are common due to the proximity of the beating heart
and movements of the shoulder girdles and the arms. The
purpose of this retrospective study was to determine the
frequency and risk factors of IA stent fractures. We also
aimed to examine the effect of stent fractures on postpro-
cedural symptoms and in-stent restenosis rates.
METHODS
This study was conducted in accordance with the Dec-
laration of Helsinki and was approved by the Semmelweis
University Ethics Committee. All participants provided
written informed consent. No compensation was provided
for participation in the study; only travel expenses were
covered.
Patient selection and lesion characteristics. All
patients who underwent IA stenting between January 1,
2000, and December 31, 2009, were included: 49 IA
lesions were treated with stent implantation in 49 patients.
Six of the 49 patients did not have a follow-up examination
because of death caused by stroke in 1 patient, at 3 months,
acute myocardial infarction in 2 patients, at 5 and
11 months, and cancer in 3 patients. The study excluded
three patients who received self-expandable stents, and
eight patients did not return for ﬂuoroscopic examination.781
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balloon-expandable stents. The procedures were per-
formed in the Heart and Vascular Center of Semmelweis
University (Budapest, Hungary).
Lesions were considered long if their length was
$20 mm. Lesions were deﬁned as heavily calciﬁed if calci-
ﬁcation was present along the entire length of the IA by
ﬂuoroscopy.
Innominate artery stenting protocol. The preproce-
dural work-up included clinical data collection (symptoms,
risk factors, which were described in detail previously,13
and medical history), radial pulse palpation and blood
pressure measurement in both arms, neurologic evaluation,
and duplex scan of the neck arteries. In recent years,
computed tomography (CT) or magnetic resonance angi-
ography have become part of the preprocedural imaging
protocol in patients with multivessel supra-aortic disease to
evaluate which lesion should be treated ﬁrst.
Acetylsalicylic acid (100 mg) was given orally for at
least 3 days before the procedure and was continued
permanently. Heparin (5000 IU) was administered intra-
arterially at the beginning of the procedure. Blood pressure
and electrocardiogram waves were monitored continu-
ously. The procedures were carried out through femoral
artery access. In patients with IA occlusion, the right
brachial artery was also punctured.
The initial diagnosis was conﬁrmed by thoracic aortog-
raphy before the stent placement in all patients. A 4F
pigtail catheter (Cordis Corp, Johnson & Johnson Co,
Miami, Fla) was inserted into the aortic arch over a stan-
dard polytetraﬂuoroethylene-coated 0.035-inch wire (J-
curved on one end, straight on the other end). Selective
catheterization (H1, JB2, or SIM2; Cordis Corp) of the
IA was performed in all patients, except those with IA
occlusion.
A hydrophilic (standard or stiff) angled-tip 0.035-inch
Terumo guidewire (Terumo Medical Corp, Tokyo, Japan)
was advanced into the IA to pass through the stenosis or
occlusion under ﬂuoroscopic control. Thereafter, the 4F
introducer sheath (Terumo Medical Corp) was exchanged
for a long 7F sheath (Cordis Corp) over a standard or
a hydrophilic stiff (Terumo) or a super-stiff 0.035-inch
Amplatz wire (Boston Scientiﬁc Corp, Natick, Mass). We
did not use embolic protection devices for the intervention.
The diameter of the patent segment and length of the
lesion were measured on selective angiograms for accurate
sizing of the stent. The indication for stent placement was
a suboptimal PTA due to unfavorable lesion morphology
(eg, heavily calciﬁed lesions, occlusions) or a failed angio-
plasty. Different balloon and stent types were used,
depending on the availability of devices and personal pref-
erence of the interventional radiologist. The angioplasty
balloons were Wanda (size, 7-10 mm  40 mm; Boston
Scientiﬁc Corp) in eight patients and Pheron (size, 7-
8 mm  40 mm; Biotronik AG, Bülach, Switzerland) in
seven. Direct stent implantation was performed without
predilatation in 17 of the 32 patients. One Bard (3%) stent
(size, 12 mm  20 mm; C.R. Bard Inc, Murray Hill, NJ)and 31 Palmaz Genesis (97%) stents (size, 8-10 mm 
19-29 mm; Cordis Corp) were deployed. When it was
necessary because of difﬁcult access due to angulation at
the origin of the IA or high-grade stenosis or occlusion,
a long Mach 1 guiding catheter (Boston Scientiﬁc Corp)
was used, and the stenosis was dilated ﬁrst with a 3- to
4-mm coronary balloon over a 0.014-inch wire then with
a 5- to 6-mm peripheral balloon, after which the stent
was easily pushed through the lesion.
On completion angiography, the IA was imaged in
a 30 to 45 right anterior oblique plane, the ipsilateral
cerebral arteries in a posteroanterior 30 to 45 (right
and left) anterior oblique and lateral planes, and the ipsilat-
eral upper extremity arteries in a posteroanterior plane.
Finally, the sheath(s) were removed and the punctured
artery(ies) were compressed manually, followed by pressure
bandage(s) overnight or, in more recent cases, the femoral
artery was closed by an Angio-Seal percutaneous closure
device (St. Jude Medical Inc, Little Canada, Minn).
Patients were discharged 1 or 2 days after the procedure.
Technical success was deﬁned as <30% residual stenosis
without dissection or extravasation, whereas clinical success
meant resolution of the symptoms.
Follow-up. Follow-up visits were scheduled at 4 weeks
and at 6 and 12 months after the stenting, and annually
thereafter. The postprocedural examinations included clin-
ical data collection, radial pulse palpation, blood pressure
measurement in both arms, and a duplex scan. On the basis
of these evaluations, patients in whom signiﬁcant IA in-
stent restenosis or reocclusion was suspected had no
palpable right radial pulse, had a blood pressure difference
($30 mm Hg) between arms, or right subclavian steal
syndrome. The suspected IA in-stent restenoses or reoc-
clusions were veriﬁed with CT angiography in symptomatic
patients.
In 2010, the patients were asked to come back for an
additional follow-up visit, when a ﬂuoroscopic evaluation
was also performed in addition to the above-mentioned
examinations. The patients were told that X-rays usually
have no side effects in the typical diagnostic range for
this examination. The high-magniﬁcation ﬂuoroscopic
examinations were done in the angiography suite (AXIOM
Artis FA; Siemens Medical Solutions AG Company, Erlan-
gen, Germany) with the following parameters: 7.5 fps, 100
to 125 kV, and 550 to 800 mA.
To visualize the implanted stents, three cine loops with
a length of three cardiac cycles were recorded in posteroan-
terior, right, and left anterior oblique 30 to 45 projec-
tions. The postprocessing was performed on a Leonardo
Workstation (Syngo 2003; Siemens Medical Solutions).
The ﬂuoroscopic images were analyzed by two experienced
interventional radiologists (K.H., B.N.) in consensus.
Stent fractures were deﬁned according to a nitinol stent
fracture classiﬁcation that has been proposed by the
Cardiovascular Institute of the South (Houma, La).14
Type I is a single-strut fracture, type II fractures represent
multiple stent fractures that can occur at different sites,
type III is a complete transverse fracture without stent
Table I. Vascular calciﬁcation, presence of in-stent
restenosis, and postprocedural symptoms in patients with









Heavy calciﬁcation 7 (64) 6 (29) .072
In-stent restenosis 2 (18) 5 (24) 1.000
Postprocedural symptoms 3 (27) 6 (29) 1.000
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verse linear fracture with stent displacement.8,14
Statistical analysis. Statistical analysis was performed
with SPSS 21.0 software (IBM Corp, Armonk, NY). The
relationship between stent fracture and other postproce-
dural variables was analyzed using the Fisher exact test. A
univariate Cox regression model was used to identify inde-
pendent baseline predictors of stent fracture. All analyses
were two-tailed, and values of P # .05 were considered
as statistically signiﬁcant.
RESULTS
Patient data. The gender distribution of the patients
was almost equal (17 men, 15 women), and their average
age was 59.4 6 12.0 years (range, 28-83 years). Major
symptoms included signs of posterior cerebral ischemia
due to vertebrobasilar insufﬁciency in 10 patients (31%),
TIA in 4 (13%), amaurosis fugax in 3 (9%), and right upper
extremity claudication in 15 (47%). No patients had signif-
icant ($70%) right common or internal carotid artery
stenosis. None of those who presented with TIAs and
amaurosis fugax had signiﬁcant carotid artery stenosis or
unstable carotid plaques on any side. According to the
medical history, 10 patients (31%) had ischemic heart
disease and nine (28%) had lower extremity arterial disease.
Atherosclerotic risk factors included smoking in 20 patients
(63%), hypertension in 22 (69%), hyperlipidemia in 19
(59%), and diabetes mellitus in 5 (16%).
Lesion characteristics. The stented lesions were de
novo stenoses in 29 patients (91%) and recurrent stenoses
after previous PTA in three (9%). The degree of stenosis
or restenosis was 60% to 89% in 27 patients (85%) and
90% to 99% in two (6%). Three patients (9%) had IA
occlusion <1 cm in length; one occlusion was an oriﬁce
lesion, and two were conﬁned to the body of the IA.
Lesions were long in 14 patients (44%). Heavily calciﬁed
lesions were detected in 13 patients (41%). Three (9%) of
the 32 lesions were circumferentially calciﬁed.
Early postprocedural period (#30 days). The tech-
nical success rate was 100%. No neurologic complications
occurred in the periprocedural period. An arteriovenous
ﬁstula developed in one patient at the femoral puncture
site, and one brachial artery thrombosis was observed.
Both patients were treated surgically. The 30-day stroke,
stroke mortality, and overall mortality rates were zero. All
patients reported improvement or resolution of the prepro-
cedural symptoms.
Follow-up period. The mean follow-up time was
33.4 6 21.0 months (range, 2-73 months). Only one
patient had less than 6 months of follow-up. In-stent
restenosis was observed in seven patients (22%), and three
of them had no palpable right radial pulse. The blood
pressure difference between the two arms was >30 mm Hg
in all patients, and duplex scan showed subclavian steal
syndrome in ﬁve patients.
Nine patients (28%) were symptomatic: two showed
signs of posterior cerebral ischemia, three had right upper
extremity claudication, and four complained of dizziness.Five of the nine symptomatic patients had in-stent resteno-
sis. The cause of symptoms in the other four patients was
degenerative neck disease. Three of the ﬁve patients with
symptomatic in-stent restenosis have already undergone,
and two have been scheduled for reintervention.
Fluoroscopic examination. Altogether, 11 stent frac-
tures (34%) were detected. Fractures were type I in 1,
type II in 4, type III in 2, and type IV in 4 patients, with
63% of the fractures predominantly in the proximal portion
of the stents.
Factors associated with stent fracture. Heavily calci-
ﬁed lesions were more common in patients with IA stent
fracture; however, the difference did not reach the statisti-
cally signiﬁcant level (P ¼ .072; Table I). The prevalence of
in-stent restenosis did not differ signiﬁcantly between the
groups with and without fracture (Table I). In case of
postprocedural symptoms, the statistical analysis did not
reveal a signiﬁcant difference between patients with and
without stent fracture (Table I). The Cox regression
analysis showed that the presence of long lesions was
associated with an increased incidence of stent fracture
(hazard ratio, 5.09; 95% conﬁdence interval, 1.33-19.48;
P ¼ .017; Table II). No correlation was found bet-
ween stent fractures and age $70 years, female gender,
smoking, hypertension, hyperlipidemia, or diabetes melli-
tus (Table II).
DISCUSSION
Stent fracture has long been recognized as a complica-
tion of endovascular procedures. Fractures, although with
varying frequencies and consequences, have been reported
in all sites where stents are deployed to resolve luminal nar-
rowing.6-12 With the exception of a few individual case
reports10,11 and a small survey of nine patients,12 this is
the only study that has examined the frequency of stent
fracture in a larger cohort of patients with IA stenting.
Our retrospective assessment of a group of 32 patients
has demonstrated that fracture is a common complication
of IA stenting. We have also found that lesion length
directly correlates with an increased fracture risk, amount-
ing to a 34% overall fracture rate in the current series. In
our survey, however, the high prevalence of stent fracture
did not have a signiﬁcant effect on symptoms and in-
stent restenosis rates.
Table II. Univariate analysis of predictors of stent
fracture after innominate artery stenting
Variables
Univariate Cox regression analysis
HR (95% CI) P value
Age $70 years 0.63 (0.14-2.95) .561
Female gender 1.15 (0.35-3.78) .821
Smoking 0.52 (0.16-1.72) .287
Hypertension 1.32 (0.35-4.96) .686
Hyperlipidemia 1.61 (0.47-5.53) .449
Diabetes mellitus 0.61 (0.08-4.80) .640
Heavy calciﬁcation 3.02 (0.88-0.35) .078
Long lesion 5.09 (1.33-19.48) .017a
CI, Conﬁdence interval; HR, hazard ratio.
aStatistically signiﬁcant.
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accomplished with high technical success (96%-100%)
and low complication rates (0%-6%),2-4 stenting has a
clear advantage over PTA in patients with complex
lesions.1,5,15-20 Parallel with the increase in the number
of IA stent implantations, the ﬁrst case reports of stent frac-
tures have also emerged.10,11 Stent fracture is most
frequently seen after revascularization of vessels, such as
the femoropopliteal (15%-37%) and superﬁcial femoral
arteries (2%-65%), where generally longer self-expandable
stents are used.6 Rupture of balloon-expandable stents is
also often detected in the vertebral, iliac, and renal arteries,
among others, with a cumulative incidence ranging
between 8% and 33%, depending on the site.6 In the
present study, we found a 34% overall fracture rate in
the IA, which is comparable to the number of structural
defects observed in other supra-aortic branches.6,8
External mechanical forces and structural design of the
stents can both be responsible for the relatively high
frequency of stent fractures in the IA. We can assume
that movements of the shoulder girdles and the arms can
result in an increased mechanical stress on the IA stents.21
In addition, the continuous expansion and contraction
caused by the proximity of the beating heart are also
presumed to contribute to the nearly 30% stent fracture
rates described in the suprathoracic vessels.6,8
The design of the implanted stent itself can substan-
tially inﬂuence the likelihood of fracture. Most of our
patients received Palmaz Genesis stents, and only one indi-
vidual was treated with a Bard stent. Although a survey by
Tsutsumi et al22 found that Palmaz stents were less likely to
rupture than S670 balloon-expandable coronary stents
deployed in the vertebral arteries, the literature contains
a large amount of data regarding the proclivity of Palmaz
stents to deformation and fracture.6
Our study found that heavily calciﬁed lesions were
more common in patients with IA stent fracture; however,
the difference did not reach the statistically signiﬁcant level.
A survey conducted on internal carotid artery stents has
found that calciﬁcation of the vessel wall showed strong
association with stent fracture.8 The risk of stent fracturewas eight times higher in the calciﬁed than in the noncalci-
ﬁed arteries.8 The most widely accepted explanation for
this ﬁnding is that calciﬁcation causes changes in the
regional wall stiffness that may lead to excessive focal pres-
sure on certain parts of the stent, hence exacerbating
fracture.
Our study revealed a signiﬁcant direct correlation
between the length of the stenotic segment and the prob-
ability of fracture. Results of previous reports appear to
indicate that the lesion length and, consequently, the stent
length has a signiﬁcant inﬂuence on the frequency of stent
fracture,6 likely because longer stents are subject to higher
radial forces, especially in their midsegment.23 These forces
over a period of time may lead to metal fatigue and even-
tually fracture.23
The fractures can be associated with higher in-stent
restenosis rates and recurrence of symptoms, but the avail-
able literature data are quite inconsistent in this regard.
Tsutsumi et al22 examined the occurrence of vertebral
artery stent fracture in a retrospective cohort of 12 patients
and detected rupture in half of the deployed coronary
stents; however, no patients had in-stent restenosis or post-
procedural ischemic symptoms. Symptomatic in-stent
restenoses or reocclusions caused by IA stent fractures
also have been reported.10,11 We identiﬁed in-stent reste-
nosis in 22% and postprocedural symptoms in 28% of our
patients after IA stenting but found no signiﬁcant correla-
tion between the presence of fracture and the recurrence of
stenosis or clinical symptoms.
The limitations of the present study leave some of our
ﬁndings incomplete: First, patients were retrospectively
enrolled into the study, and the results represent an expe-
rience acquired in a single institution.
Second, owing to the retrospective nature of patient
selection, follow-up protocols were not uniform, and
complete follow-up data were not available in all patients.
Third, given the small number of nine patients who
had preprocedural CT angiography, digital subtraction
angiography and ﬂuoroscopy were used to assess vascular
calciﬁcation, both of which are poor imaging modalities
for this purpose.
Fourth, the series included only three short (<1 cm)
chronic total occlusions, indicating that the results of this
study do not necessarily apply to chronic total occlusions.
Fifth, Palmaz stents were implanted in most patients;
thus, we cannot discern the performance of different stent
designs, such as covered balloon-expandable stents, which
are more frequently used for these lesions.
Most of the fractured stents remained asymptomatic,
but validation by independent cohorts might be necessary
to reach deﬁnite conclusions on the clinical and therapeutic
consequences of IA stent fractures.CONCLUSIONS
Even if stents deployed in the brachiocephalic trunk
possess a relatively high fracture risk, especially in patients
with long lesions ($20 mm), the occurrence of IA stent
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 3 Dósa et al 785fracture does not signiﬁcantly correlate with clinical
outcome.
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